Galderma Group AG
1GALD
Company Profile
Business description
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs around 7,00 people.
Contact
Zahlerweg 10
Zug6300
CHET: +41 584558592
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.80 | 0.80 | -0.01% |
| CAC 40 | 8,149.50 | 18.65 | -0.23% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,258.32 | 108.74 | -0.22% |
| FTSE 100 | 9,931.38 | 9.33 | -0.09% |
| HKSE | 25,630.54 | 224.06 | -0.87% |
| NASDAQ | 23,374.63 | 44.45 | -0.19% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,881.83 | 14.41 | -0.21% |
| S&P/ASX 200 | 8,714.30 | 0.50 | -0.01% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |